• Home
  • Contact
(800) 605-8422 Toll Free
Diagnomics
×
  • Consumer Genomics Solutions
  • Analysis Platform
    • MICROARRAY
    • NGS
    • OPENARRAY
  • Research Services
    • CLINICAL/TRANSLATION RESEARCH
    • ASSAY DEVELOPMENT
    • Bioinformatics
    • Diagnomics on Cloud
    • My AccuGenie
  • News
    • Diagnomics
    • Amazing Science
  • About us
    • Terms of Service
    • Privacy Policy

Diagnomics Celebrates the Announcement of the Successful Initial Public Offering (IPO) and Listing of Eone-Diagnomics Genome Center (EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ)

Diagnomics Celebrates the Announcement of the Successful Initial Public Offering (IPO) and Listing of Eone-Diagnomics Genome Center (EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ)
July 3, 2018Diagnomics

SAN DIEGO, July 2, 2018 – Diagnomics, Inc., a leading provider for precision medicine solutions based on genomics technology, proudly shares the announcement of the successful initial public offering (IPO) and listing of Eone-Diagnomics Genome Center (ticker symbol; EDGC) on the Korea Securities Dealer Automated Quotation (KOSDAQ) on June 26, 2018.

 

Eone-Diagnomics Genome Center (EDGC) is an international joint venture established in 2013 between the largest clinical laboratory in South Korea, Eone Life Science, in Incheon, South Korea and Diagnomics Inc. in California, USA. EDGC offers cutting-edge products and services in clinical and consumer genetics, ushering forth innovation in healthcare based on big-data and genome analysis utilizing next generation sequencing (NGS) and array technologies.

 

EDGC has been recognized as one of the most popular listings in KOSDAQ market as an international joint venture in biotechnology.  Many foreign companies view EDGC’s IPO as a prominent success story, spotlighting Korea to be an ideal country for international business cooperation in emerging biotechnology and healthcare fields. The company said the IPO would promote further global cooperation and market expansion through leading-edge technologies and product development.

 

“This is exciting news for EDGC, their employees, their customers, and investors,” said Dr. Byung-In Lee, CEO of Diagnomics. “This extraordinarily talented and capable team of professionals worked hard to make this happen and we are proud to be a part of this successful joint venture with Eone Laboratories, demonstrating a big step toward the international reach and impact of the Diagnomics team in San Diego.” Dr. Min Seob Lee, co-CEO of EDGC and a founder of Diagnomics and EDGC stated, “This was a highly competitive IPO and a historical landmark as an international joint venture in the biotech­nology industry. We are looking forward to collaborating our respective strengths and furthering our reach as a leader in the global genomics market, advancing the impact of genomics in health.”

 

 

About Diagnomics

 

Diagnomics, Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. We strive to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market.

 

Diagnomics is a CLIA-certified, CAP-accredited, and HIPAA-compliant laboratory providing genetic testing platform services and cloud-based analysis solutions. To learn more, visit www.diagnomics.com

 

 

Contact: Byung-In Lee

Telephone: (760) 310-5984

Main Number: (800) 605-8422

Email: info@diagnomics.com

Website: www.diagnomics.com

Recent Posts

  • Diagnomics Releases Cardiovascular Health Panel on Clinical Microarray Platform
  • Visit our booth #643 at ASHG 2019, October 15-17 in Houson!
  • Diagnomics Added CLIA Certificates From Maryland, Pennsylvania, and Rhode Island
  • Visit our booth #1107 at ACMG 2019, April 3 – 5 in Seattle!
  • Diagnomics Introduces ACMG 59 Reports for Personalized Genetic Testing

Recent Comments

    Archives

    • October 2019
    • September 2019
    • March 2019
    • January 2019
    • November 2018
    • October 2018
    • September 2018
    • July 2018
    • March 2018
    • April 2017
    • December 2016
    • June 2016
    • May 2016

    Categories

    • Amazing Science
    • Diagnomics

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Diagnomics Mission

    Diagnomics Mission

    Diagnomics, Inc. is a trusted provider of innovative genetic testing platforms for both organizations and individual consumers. We strive to deliver confidence and reliability by offering comprehensive genomic solutions for the development of personalized healthcare and precision medicine in the global genomics market.

    Diagnomics is a CLIA-certified, CAP-accredited, and HIPAA-compliant laboratory providing genetic testing platform services and cloud-based analysis solutions.

    (800) 605-8422

    info@diagnomics.com

    www.diagnomics.com

    5050 Murphy Canyon Rd ste 150, San Diego, CA 92123

    Latest News

    • Diagnomics Releases Cardiovascular Health Panel on Clinical Microarray Platform Oct 7

      SAN DIEGO, October 7, 2019 (Newswire.com) –​Diagnomics Inc., a San...

    • Visit our booth #643 at ASHG 2019, October 15-17 in Houson! Sep 16

      Don’t miss out the largest human genetics meeting in the...

    • Diagnomics Added CLIA Certificates From Maryland, Pennsylvania, and Rhode Island Sep 9

      Diagnomics, a leading genomics services provider, announced that it now...

    • Visit our booth #1107 at ACMG 2019, April 3 – 5 in Seattle! Mar 20

       

    Legal Info

    Research Consent
    Copyright ©2018 all rights reserved
    Diagnomics, Inc.